Stock analysts at Piper Jaffray Companies began coverage on shares of Motus GI (NASDAQ:MOTS) in a research note issued to investors on Sunday. The firm set an “overweight” rating and a $7.00 price target on the stock. Piper Jaffray Companies’ price objective would indicate a potential upside of 45.53% from the stock’s current price.
Shares of Motus GI (MOTS) opened at $4.81 on Friday. The stock has a market capitalization of $74.91 and a P/E ratio of -6.41. Motus GI has a 52-week low of $3.75 and a 52-week high of $5.30.
In other Motus GI news, CEO Mark Pomeranz acquired 8,000 shares of the stock in a transaction that occurred on Friday, February 16th. The stock was bought at an average cost of $5.00 per share, for a total transaction of $40,000.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Chairman David P. Hochman acquired 115,000 shares of the stock in a transaction that occurred on Friday, February 16th. The stock was acquired at an average price of $5.00 per share, with a total value of $575,000.00. The disclosure for this purchase can be found here. Insiders purchased 1,175,000 shares of company stock valued at $5,875,000 over the last quarter.
Motus GI Holdings, Inc is a medical technology company. The Company is developing Pure-Vu system that integrates with existing colonoscopes to cleanse poorly prepped colons during the colonoscopy procedure. The Pure-Vu system uses a precise mixture of water and air to loosen debris from the colon mucosa while simultaneously evacuating the bowel contents, clearing the way for the endoscopist to perform a high quality examination, even when the patient is not fully clean prior to their procedure.
Receive News & Ratings for Motus GI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Motus GI and related companies with MarketBeat.com's FREE daily email newsletter.